LFCR
Lifecore Biomedical, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.40
−1.84%Price chart
Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30
Key dataOct 30, 2026
Open$6.49
From 52W high−27.44%
Volume1.02M
Market cap$242.60M
P/E (TTM)—
P/S (TTM)1.9x
Div yield—
Key dataOct 30, 2026
Open
$6.49
From 52W high
−27.44%
Volume
1.02M
Market cap
$242.60M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
64.4
MomentumView details →
1D Return
−1.84%
YTD Return
−21.94%
SummaryUpdated Dec 1, 2026
Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a specialized pharmaceutical contract development and manufacturing organization that was originally incorporated as Landec Corporation in 1986 before changing its name in November 2022. The company went public in 1996 and is headquartered in Santa Maria, California. Lifecore operates as an integrated contract development and manufacturing organization (CDMO) with a particular focus on hyaluronic acid-based pharmaceutical products and aseptic fill-finish services for injectable medications.
Similar companies
Latest newsMore news →
Lifecore Biomedical, Inc. signed an Agreement and Plan of Merger under which a merger subsidiary of the parent will merge into Lifecore, which will survive as a wholly owned subsidiary, with each share converted into $6.28 in cash plus one contingent value right.32d agoWebster Equity Partners agreed to acquire Lifecore Biomedical.32d agoLifeCore Biomedical, Inc. reported its Q2 2026 financial results with total revenue of $34.2 million, a net loss of $6.2 million, and diluted EPS of -$0.19.87d ago